Ionis Pharmaceuticals, Inc.
IONS
NASDAQ·Healthcare·Biotechnology·Mkt cap $9.7B
$58.09
▼ -0.07%
P/E
-16.79
Mkt Cap
$9.7B
52-Wk Range
$50.01–$86.74
52-Week Range
$50.01 - $86.74
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 4.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary antisense oligonucleotide (ASO) platform technology
- Multiple FDA-approved marketed products with high barriers to entry
- Strategic partnerships with major pharmaceutical companies (Biogen, AstraZeneca, Roche, GSK, Novartis)
- Deep pipeline with multiple Phase 3 candidates addressing unmet medical needs
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Stable outlook
Expansion of marketed product uptake and label extensions in existing indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-21.0% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IONS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
JUL 29, 2026
Reported EPS of -$0.69 vs -$1.08 consensus (+36.1% surprise). Revenue of $268.0M vs $189.1M expected (+41.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+36.1%
Revenue trend · last 8Q
—
—
—
+101%
+17%
-10%
+87%
-41%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$133.8M
$226.6M
$131.6M
$452.0M
$156.7M
$203.0M
$246.1M
$267.9M
Margins · last 8Q
Gross
99.0%
Operating
-38.2%
Profit
-42.8%
Wall Street consensus
13 analysts · 77% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
77%
Hold
23%
Sell
0%
Median Price Target
—
Latest: Citi · Sep 7, 2026
vs Industry
How IONS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related